The Test That Could Catch Pancreatic Cancer Before It's Deadly

Are we really close to catching pancreatic cancer early? This silent killer still kills 75% within the first year of diagnosis. But what if we could spot clues before it becomes deadly? Transforming Pancreatic Cancer Detection with Amplified SciencesIn this episode, Bradley Bostic hosts Diana Caldwell, CEO and co-founder of Amplified Sciences, to explore groundbreaking advancements in early detection of pancreatic cancer. Given the devastating prognosis of late-stage diagnosis, their discussion highlights how innovative diagnostics can shift the paradigm towards earlier, less invasive screening—saving lives and improving outcomes.Main insights: The dire statistics of pancreatic cancer survival rates highlight an urgent need for better screening. Amplified Sciences has developed a multi-omics approach that detects precancerous cysts, much like colon polyps, allowing preemptive intervention. The current standard, often reactive, diagnosis leads to late-stage detection; the new method aims to identify risks before symptoms appear. They discuss the importance of high negative predictive value (NPV) to rule out malignancy non-invasively. The platform uses minimal cyst fluid — only 10 times less than existing tests — crucial for small lesions. The approach combines various biomarkers (proteomic, enzymatic, genetic) to improve accuracy. Blood-based screening for early detection remains challenging, but amplification of fluid samples offers more precise insights. Regulatory milestones, like CAP accreditation, position Amplified Sciences for wider clinical adoption. Payer and coverage discussions are ongoing but vital for making this technology accessible. The episode emphasizes how technological innovation, multidisciplinary collaboration, and early detection can revolutionize pancreatic cancer care. Timestamps: 00:11 - Introduction and personal story highlighting the importance of early cancer detection 01:08 - Diana Caldwell's background and motivation to improve gastroenterology diagnostics 04:38 - The science behind Amplified Sciences' diagnostic platform and research origins 07:27 - Current challenges in pancreatic cancer diagnosis and the limitations of standard tests 09:18 - Understanding the brutal statistics and silent progression of pancreatic cancer 10:12 - How genetic factors and incidental screening can identify high-risk individuals 12:41 - The patient journey: from incidental detection to invasive procedures and unmet needs 14:15 - The role of the PANSIS Pro test, regulatory milestones, and sample requirements 16:03 - Differentiating between benign cysts and pre-malignant lesions like IPMN 17:24 - The significance of multi-omic diagnostics and reducing unnecessary surgeries 21:18 - Screening strategies: incidentally detected lesions and the importance of size and location 24:04 - Limitations of current biomarkers like CA 19-9 and the promise of multi-marker panels 26:02 - The unique approach of liquid-focused diagnostics versus traditional blood tests 29:18 - Reimbursement hurdles and the importance of demonstrating clinical utility 32:13 - The mental health impact of uncertain diagnoses and proactive testing benefits 33:55 - The vision for a future where early detection becomes routine and standard careResources & Links: Resources & Links: Amplified Sciences Official Website: https://amplifiedsciences.com/ Connect with Diana Caldwell on LinkedIn: https://www.linkedin.com/in/dianathompsoncaldwell/ This episode underscores the power of innovative diagnostics to intercept pancreatic cancer early, transforming a deadly prognosis into manageable health outcomes. It highlights the collaborative effort needed across research, regulation, and healthcare platforms to ensure these breakthroughs reach patients.